Page last updated: 2024-09-05

sorafenib and MEA 2a

sorafenib has been researched along with MEA 2a in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barford, D; Gambacorti-Passerini, C; Hofstra, RM; Isacke, CM; Links, TP; Magee, AI; Mologni, L; Plaza-Menacho, I; Sala, E	1

Other Studies

1 other study(ies) available for sorafenib and MEA 2a

Article	Year
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. The Journal of biological chemistry, 2007, Oct-05, Volume: 282, Issue:40 Topics: Benzenesulfonates; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50; Lysosomes; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Endocrine Neoplasia Type 2a; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Pyridines; Sorafenib	2007

Article

Year

Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.

The Journal of biological chemistry, 2007, Oct-05, Volume: 282, Issue:40

Topics: Benzenesulfonates; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50; Lysosomes; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Endocrine Neoplasia Type 2a; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Pyridines; Sorafenib

2007